New Zealand's Medsafe approves first medicine under new verification pathway
Singapore, Nov. 17 -- New Zealand's medical regulatory body Medsafe has approved a generic brand of paliperidone injection under the new verification approval pathway, saving several months of work without compromising on safety.
The medicine, which was approved in 25 working days, was the first to be approved under the rule of two verification pathway which allows Medsafe to approve a medicine if it has already met the standards of two recognised overseas regulators.
Rather than repeating a full assessment, Medsafe focused on New Zealand-specific factors and verified that the medicine proposed for New Zealand was the same as the product approved overseas. The approach saved Medsafe around 10 months' worth of assessment time.
Paliperid...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.